Notably, transcriptional downregulation of KRAS has been demonstrated to be lethal to tumor cells with aberrant KRAS signaling, irrespective of mutational status, and to have a wide potential therapeutic window [1,18,19,20,21]. The gene discussed is KRAS; the disease is neoplasm.